MARKET

KROS

KROS

Keros Therapeutics, Inc.
NASDAQ
20.13
-0.70
-3.36%
After Hours: 20.13 0 0.00% 17:40 12/18 EST
OPEN
20.74
PREV CLOSE
20.83
HIGH
21.05
LOW
19.84
VOLUME
590.66K
TURNOVER
--
52 WEEK HIGH
22.55
52 WEEK LOW
9.12
MARKET CAP
613.28M
P/E (TTM)
13.04
1D
5D
1M
3M
1Y
5Y
1D
Wells Fargo Remains a Buy on Keros Therapeutics (KROS)
TipRanks · 8h ago
Stocks will continue to broaden beyond the mega-caps in 2026 – Charles Schwab’s Liz Ann Sonders
Seeking Alpha · 2d ago
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
NASDAQ · 2d ago
Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros
NASDAQ · 2d ago
Buy These 5 Best Value Stocks to Boost Your Portfolio in December
NASDAQ · 3d ago
Weekly Report: what happened at KROS last week (1208-1212)?
Weekly Report · 3d ago
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?
NASDAQ · 6d ago
Weekly Report: what happened at KROS last week (1201-1205)?
Weekly Report · 12/08 10:10
More
About KROS
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Webull offers Keros Therapeutics Inc stock information, including NASDAQ: KROS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KROS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KROS stock methods without spending real money on the virtual paper trading platform.